Multiple Sclerosis, Chronic Progressive
"Multiple Sclerosis, Chronic Progressive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis, Chronic Progressive".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis, Chronic Progressive".
This graph shows the total number of publications written about "Multiple Sclerosis, Chronic Progressive" by people in Harvard Catalyst Profiles by year, and whether "Multiple Sclerosis, Chronic Progressive" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Multiple Sclerosis, Chronic Progressive" by people in Profiles.
External validation of a clinical prediction model in multiple sclerosis. Mult Scler. 2023 Feb; 29(2):261-269.
Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients. Mult Scler. 2023 Feb; 29(2):206-211.
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2023 01; 10(1).
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 01; 10(1).
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022 11; 9(6).
Reader Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Neurology. 2022 10 04; 99(14):630-631.
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. J Neurol Neurosurg Psychiatry. 2023 01; 94(1):23-30.
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis. Mult Scler. 2023 01; 29(1):92-106.
Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis. Ann Neurol. 2022 07; 92(1):87-96.
Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Qual Life Res. 2022 Jun; 31(6):1799-1805.